Orchard Therapeutics PLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.81
- Today's High:
- $5.08
- Open Price:
- $4.81
- 52W Low:
- $3.601
- 52W High:
- $7.2
- Prev. Close:
- $4.83
- Volume:
- 80093
Company Statistics
- Market Cap.:
- $112.48 million
- Book Value:
- 4.799
- Revenue TTM:
- $21.31 million
- Operating Margin TTM:
- -497.83%
- Gross Profit TTM:
- $-76515000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.99%
- Return on Equity TTM:
- -66.71%
Company Profile
Orchard Therapeutics PLC had its IPO on 2018-10-31 under the ticker symbol ORTX.
The company operates in the Healthcare sector and Biotechnology industry. Orchard Therapeutics PLC has a staff strength of 166 employees.
Stock update
Shares of Orchard Therapeutics PLC opened at $4.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.81 - $5.08, and closed at $5.08.
This is a +5.18% increase from the previous day's closing price.
A total volume of 80,093 shares were traded at the close of the day’s session.
In the last one week, shares of Orchard Therapeutics PLC have increased by +2.63%.
Orchard Therapeutics PLC's Key Ratios
Orchard Therapeutics PLC has a market cap of $112.48 million, indicating a price to book ratio of 0.4506 and a price to sales ratio of 3.4512.
In the last 12-months Orchard Therapeutics PLC’s revenue was $21.31 million with a gross profit of $-76515000 and an EBITDA of $-103435000. The EBITDA ratio measures Orchard Therapeutics PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Orchard Therapeutics PLC’s operating margin was -497.83% while its return on assets stood at -26.99% with a return of equity of -66.71%.
In Q2, Orchard Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 67.4%.
Orchard Therapeutics PLC’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-6.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Orchard Therapeutics PLC’s profitability.
Orchard Therapeutics PLC stock is trading at a EV to sales ratio of 24.1888 and a EV to EBITDA ratio of 0.1852. Its price to sales ratio in the trailing 12-months stood at 3.4512.
Orchard Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $232.30 million
- Total Liabilities
- $57.52 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $31000
- Dividend Payout Ratio
- 0%
Orchard Therapeutics PLC ended 2024 with $232.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $232.30 million while shareholder equity stood at $109.05 million.
Orchard Therapeutics PLC ended 2024 with $0 in deferred long-term liabilities, $57.52 million in other current liabilities, 29456000.00 in common stock, $-930603000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.27 million and cash and short-term investments were $150.74 million. The company’s total short-term debt was $16,029,000 while long-term debt stood at $18.44 million.
Orchard Therapeutics PLC’s total current assets stands at $181.29 million while long-term investments were $0 and short-term investments were $112.47 million. Its net receivables were $18.07 million compared to accounts payable of $6.95 million and inventory worth $6.94 million.
In 2024, Orchard Therapeutics PLC's operating cash flow was $0 while its capital expenditure stood at $31000.
Comparatively, Orchard Therapeutics PLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $5.08
- 52-Week High
- $7.2
- 52-Week Low
- $3.601
- Analyst Target Price
- $20.75
Orchard Therapeutics PLC stock is currently trading at $5.08 per share. It touched a 52-week high of $7.2 and a 52-week low of $7.2. Analysts tracking the stock have a 12-month average target price of $20.75.
Its 50-day moving average was $5.07 and 200-day moving average was $5.08 The short ratio stood at 0.33 indicating a short percent outstanding of 0%.
Around 1327% of the company’s stock are held by insiders while 3788.5% are held by institutions.
Frequently Asked Questions About Orchard Therapeutics PLC
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.